COVID-19 大流行迫使医疗机构缩减业务规模。患者行为的变化似乎正在产生影响。我们进行了一项调查，目的是回顾大流行期间肺癌治疗并找出问题。我们检查了我院2017年至2022年所有病理诊断为非小细胞肺癌（NSCLC）患者的病历。NSCLC患者分为两组：2017年至2019年期间诊断的患者（第一期）和2020年至2022年期间诊断的患者（第二期）。在研究期间，267名NSCLC患者（第一期：147名患者，第二期：121名患者）被纳入研究在我们医院确诊。两个研究期间的患者在年龄（p=0.613）、ECOG表现状态（p=0.125）和临床分期（p=0.354）方面没有显着差异。与第一阶段的 4.24 cm ± 1.76 相比，第二阶段的肿瘤尺寸明显更大，平均值为 5.88 cm ± 3.02 (p<0.001)。在标准治疗组中，第一期的中位生存时间为457天，第二期的中位生存时间为313天（p=0.063）。在最佳支持治疗组中，第一阶段的中位生存时间为122天，第二阶段的中位生存时间为57天（p=0.004）。在大流行期间，患者自己没有寻求肺癌治疗的咨询。如何减少因咨询受到抑制而造成的延误尚无定论，但这是未来的一个重要问题。版权所有 2023，国际抗癌研究所。

The COVID-19 pandemic has forced medical institutions to scale back their practice. Changes in patient behavior seemed to be having an impact. We conducted a survey with the aim of reviewing lung cancer treatment during the pandemic period and identifying problems.We examined the medical records of all patients pathologically diagnosed with non-small cell lung cancer (NSCLC) in our hospital from 2017 to 2022. NSCLC patients were divided into two groups: those diagnosed between 2017 and 2019 (first period) and those diagnosed between 2020 and 2022 (second period).Within the study period, 267 NSCLC patients (first period: 147 patients, second period: 121 patients) were diagnosed in our hospital. The patients in the two study periods did not differ significantly in age (p=0.613), ECOG performance status (p=0.125), and clinical stage (p=0.354). Tumor size was significantly larger in the second period with a mean of 5.88 cm ± 3.02, compared to 4.24 cm ± 1.76 in the first period (p<0.001). In the standard treatment group, the median survival time was 457 days in the first period and 313 days in the second period (p=0.063). In the best supportive care group, median survival time was 122 days in the first period and 57 days in the second period (p=0.004).Patients themselves refrained from seeking consultation for lung cancer treatment during the pandemic period. It is inconclusive how to reduce the delay due to the suppression of consultations, but this is an important issue for the future.Copyright 2023, International Institute of Anticancer Research.